Bolt Biotherapeutics (BOLT)

• Market cap: $9.94M
• 1 day: -1.71%
• 5 days: -1.15%
• 1 month: -5.82%
• 3 months: -16.85%
• 6 months: -35.73%
• Year to date: -54.56%
• 1 year: -58.09%
• 5 years: -99.19%
• 10 years: -99.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Employees: 52

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

44.03% more ownership

Funds ownership: 2.39% [Q1] → 46.42% (+44.03%) [Q2]

14% less funds holding

Funds holding: 29 [Q1] → 25 (-4) [Q2]

30% less capital invested

Capital invested by funds: $7.33M [Q1] → $5.1M (-$2.23M) [Q2]

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $75
• Avg. target: $75
• High target: $75

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Chad Messer

$75

Buy Maintained

15 Aug 2025